Administering capecitabine after surgery extends survival by a median of 17 months compared with surgery alone for patients with biliary tract cancer, according to research that will be presented at the 2017 ASCO...
Administering capecitabine after surgery extends survival by a median of 17 months compared with surgery alone for patients with biliary tract cancer, according to research that will be presented at the 2017 ASCO...
...